Myasthenia Gravis
📧 Sign up to get email alerts when something new happens for Myasthenia Gravis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases [NA]
A clinical trial evaluating EVM18001 for refractory autoimmune diseases is currently recruiting, including systemic lupus erythematosus, sys…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating Nipocalimab in children aged 2 to under 18 with generalized Myasthenia Gravis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis [Phase 3]
A Phase 3 clinical trial update describing the long-term safety and efficacy evaluation of rozanolixizumab in adult participants with ocular…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Myasthenia Gravis Inebilizumab Trial [Phase 3]
Phase 3 trial update of inebilizumab for myasthenia gravis has posted results; the study is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG) [Phase 4]
Phase 4 clinical trial evaluating subcutaneous efgartigimod for adults with newly diagnosed generalized myasthenia gravis is currently recru…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis [NA]
A pediatric trial evaluating the efficacy and safety of Telitacicept for ocular myasthenia gravis in children. The study status is not yet r…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases [Phase 2]
Phase 2 clinical trial investigating autologous stem cell transplant for neurologic autoimmune diseases is currently active but not recruiti…
-
FDA approval · 2026-02-26FDA Approved: VYVGART HYTRULO — Supplemental Application (argenx US)
The FDA approved a supplemental application for Vyvgart HYTRULO (efgartigimod alfa and hyaluronidase) submitted by argenx US.
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases [Phase 1]
Phase 1 study of Anitocabtagene Autoleucel for non-oncology plasma cell-related diseases is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Effect of Dexmedetomidine Versus Dexamethasone as Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Plane Block on Postoperative Analgesia in Myasthenic Patients Undergoing Thoracoscopic Thymectomy [NA]
A clinical trial update describing a study that compares dexmedetomidine versus dexamethasone as adjuvants to bupivacaine in an ultrasound-g…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of Life
A completed clinical trial assessed cognitive functioning in people with Myasthenia Gravis and its impact on daily activities, work, disabil…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Evaluation of the Condition of Patients Receiving EARLY Ravulizumab and Admitted in ICU for gMG Crisis
A recruiting study is evaluating early ravulizumab administration in ICU-admitted patients with generalized Myasthenia Gravis crisis.
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
A worldwide pregnancy safety study is recruiting to assess maternal, fetal, and infant outcomes after exposure to efgartigimod during pregna…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
This update outlines a non-interventional, post-authorization safety study of patients treated with efgartigimod alfa for myasthenia gravis,…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG) [NA]
This clinical trial update notes termination of the HN2301 study in refractory myasthenia gravis and mentions efficacy and safety data, thou…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases [EARLY_Phase 1]
This document reports an early-phase (Phase 1) clinical trial of QT-019C UCAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory …
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis [Phase 1, Phase 2]
A Phase 1b/2 trial of IM-101 in adults with generalized and ocular myasthenia gravis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
A long-term follow-up study for participants previously treated with KYV-101; recruitment is ongoing across multiple autoimmune diseases.
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) [Phase 1]
A Phase 1 study evaluating CC-97540 in relapsing and progressive forms of multiple sclerosis and refractory myasthenia gravis is currently r…
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: A Study of RD06-04 in Patients With Active Autoimmune Diseases [EARLY_Phase 1]
A early Phase 1 study of RD06-04 in active autoimmune diseases has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases [EARLY_Phase 1]
Early-phase clinical study of a targeted CD19/BCMA CAR-T therapy for autoimmune diseases is recruiting, including systemic lupus erythematos…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Detecting Fatigue From Voice in Generalised Myasthenia Gravis
Thymia Limited is conducting a clinical trial to detect fatigue from voice in generalized myasthenia gravis; the study status is NOT_YET_REC…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Ripertamab for the Treatment of Myasthenia Gravis [Phase 1, Phase 2]
Phase 1/Phase 2 clinical trial update for Ripertamab in Myasthenia Gravis. The study is currently not yet recruiting.
-
EMA approval · 2026-01-23EMA Authorised: Vyvgart (efgartigimod alfa) — Argenx
The European Medicines Agency has authorised Vyvgart (efgartigimod alfa) for the treatment of myasthenia gravis and chronic inflammatory dem…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases [EARLY_Phase 1]
An early-phase UCAR-T therapy targeting CD19/BCMA is being evaluated for relapsing or refractory multiple sclerosis, myasthenia gravis, CIDP…